Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Tradipitant: First Approval.

Drugs·2026

Same author

Depemokimab: First Approval.

Drugs·2026

Same author

Sibeprenlimab: First Approval.

Drugs·2026

Same author

Zongertinib: First Approval.

Drugs·2026

Same author

Rilzabrutinib: First Approval.

Drugs·2025

Same author

Dorocubicel: First Approval.

Molecular diagnosis & therapy·2025

Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026

Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026

Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026

Same journal

Relacorilant: First Approval.

Drugs·2026

Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026

Same journal

Linerixibat: First Approval.

Drugs·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Aug 6, 2025

Orthotopic Xenografting of Human Luciferase-Tagged Malignant Peripheral Nerve Sheath Tumor Cells for in vivo Testing of Candidate Therapeutic Agents

Orthotopic Xenografting of Human Luciferase-Tagged Malignant Peripheral Nerve Sheath Tumor Cells for in vivo Testing of Candidate Therapeutic Agents

Published on: March 7, 2011

Ublituximab: First Approval.

¹Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

|March 15, 2023

Summary

This summary is machine-generated.

Ublituximab, a new anti-CD20 therapy, offers a twice-yearly infusion option for multiple sclerosis treatment. It targets B cells, crucial in MS pathogenesis, and received US approval in December 2022.

More Related Videos

Minimally Invasive Establishment of Murine Orthotopic Bladder Xenografts

Minimally Invasive Establishment of Murine Orthotopic Bladder Xenografts

Published on: February 11, 2014

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Related Experiment Videos

Last Updated: Aug 6, 2025

Orthotopic Xenografting of Human Luciferase-Tagged Malignant Peripheral Nerve Sheath Tumor Cells for in vivo Testing of Candidate Therapeutic Agents

Orthotopic Xenografting of Human Luciferase-Tagged Malignant Peripheral Nerve Sheath Tumor Cells for in vivo Testing of Candidate Therapeutic Agents

Published on: March 7, 2011

Minimally Invasive Establishment of Murine Orthotopic Bladder Xenografts

Minimally Invasive Establishment of Murine Orthotopic Bladder Xenografts

Published on: February 11, 2014

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Area of Science:

Immunology
Neurology
Pharmacology

Background:

Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
B cells play a significant role in the pathogenesis of MS.
Current MS treatments aim to modulate the immune system to reduce disease activity.

Purpose of the Study:

To summarize the development milestones of ublituximab.
To highlight the first global approval of ublituximab for multiple sclerosis.

Main Methods:

Ublituximab is a glycoengineered anti-CD20 monoclonal antibody.
Its mechanism involves B cell depletion through antibody-dependent cellular cytotoxicity.
Development focused on optimizing administration for patient convenience.

Main Results:

Ublituximab is the first anti-CD20 therapy with a twice-yearly, one-hour infusion schedule after initial doses.
Received first global approval in the USA in December 2022.
Approved for adults with relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

Conclusions:

Ublituximab represents a novel therapeutic option for relapsing forms of MS.
Its development signifies progress in targeted B cell depletion therapies.
The convenient dosing regimen may improve patient adherence and outcomes.